Suraksha
Clinic & Diagnostics

Date: 12 August, 2026

To

The Secretary	The Secretary
BSE Limited	**The National Stock Exchange of India Limited**
Phiroze Jeejeebhoy Towers	Exchange Plaza, Plot No. C/1. G Block
Dalal Street	Bandra -Kurla Complex, Bandra (East)
Mumbai - 400 001	Mumbai- 400 051
Scrip Code: 544293	**Scrip Symbol : SURAKSHA**

Dear Sir / Ma'am,

Sub: Outcome of the Board meeting held today i.e. Wednesday, 12 August, 2026

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations') as amended from time to time

Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') as amended from time to time, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. on Wednesday, 12 August, 2026, *inter alia*, considered and approved/ noted the following:

1. Approved the unaudited financial results (standalone and consolidated) of the Company for the quarter ended 30 June, 2026 and the same is enclosed along with the Limited Review Report issued by the Statutory Auditors of the Company, pursuant to Regulation 33 of SEBI Listing Regulations marked as **"Annexure-A";**

2. Based on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, appointment of Mr. Dinesh Gupta as the Chief Financial Officer of the Company with effect from 24 August 2026, who will also act as a Group Chief Financial Officer of the Company

   The details as required under Schedule III - Para A (7) of Part A of Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular dated January 30, 2026 is marked as "**Annexure-B**"**;**

3. Approved the revised Notice convening the 21st Annual General Meeting of the Company for the financial year 2025-26, to be held on Tuesday, 22 September 2026 through video conferencing/ other audio-visual means ('VC/OAVM').

4. Fixed Tuesday, 15 September 2026, as the Record Date, for the purpose of determining the entitlement of the shareholders to receive dividend for the financial year ended 31 March 2026. The dividend, if approved by the shareholders at the 21st AGM, shall be paid within the statutory period prescribed under the Companies Act, 2013.

Suraksha
Clinic & Diagnostics

The aforesaid financial results are also being made available on the Company's website at www.surakshanet.com.

Please note that the meeting commenced at 03:00 P.M. (IST) and concluded at 04:30 P.M. (IST).

You are requested to take the same on record.

Thanking you.

For Suraksha Diagnostic Limited

RITU MITTAL

Digitally signed by RITU MITTAL
Date: 2026.08.12 17:22:03 +05'30'

____

Ritu Mittal
Joint Managing Director & CEO
DIN: 00165886

Encl.: as above

Suraksha Diagnostic Limited
(Formerly known as Suraksha Diagnostic Private Limited)
CIN: L85110WB2005PLC102265
Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I **Website:** www.surakshanet.com
Phone:(033) 6605 9750

Annexure A

MSKA & Associates LLP
(Formerly known as M S K A & Associates)
Chartered Accountants

Infinity Benchmark, Unit 1302
13th Floor, Plot No. G-1, Block - EP & GP
Sector - V, Salt Lake
Kolkata, West Bengal 700 091

Independent Auditor's Review Report on unaudited standalone financial results of Suraksha Diagnostic Limited for the quarter ended June 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Dipak Jaiswal
Partner
Membership No.: 063682
UDIN: 26063682BTDNUY8S03
Place: Kolkata
Date: 12 August 2026

MSKA & ASSOCIATES LLP Chartered Accountants

Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited standalone financial results for the quarter ended 30 June 2026

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30 June 2026 (Unaudited)	31 March 2026 (Audited) (Refer Note 2)	30 June 2025 (Unaudited)	31 March 2026 (Audited)
Income				
I Revenue from operations	8,408.62	7,855.59	7,027.90	30,067.91
II Other income	156.41	130.28	109.57	435.23
III **Total Income**	**8,565.03**	**7,985.87**	**7,137.47**	**30,503.14**
IV **Expenses**				
Cost of materials consumed	971.16	1,003.18	868.80	3,610.01
Employee benefits expenses	1,385.26	1,323.23	1,241.48	5,167.00
Finance costs	367.00	386.52	265.85	1,233.99
Depreciation and amortisation expense	1,060.09	1,068.56	915.37	3,960.15
Impairment loss/(gain)	75.96	29.45	(89.04)	46.71
Other expenses	3,084.32	3,119.21	2,622.93	11,763.77
Total expenses (IV)	**6,943.79**	**6,930.15**	**5,825.39**	**25,781.63**
V **Profit before tax and exceptional items (III-IV)**	**1,621.24**	**1,055.72**	**1,312.08**	**4,721.51**
VI Exceptional items	-	-	-	-
VII **Profit before tax (V-VI)**	**1,621.24**	**1,055.72**	**1,312.08**	**4,721.51**
VIII **Income tax expense**				
(i) Current tax expense	407.92	239.31	285.67	1,072.82
(ii) Tax pertaining to earlier year	11.39	-	-	-
(iii) Deferred tax expense/(credit)	(56.27)	145.49	41.54	242.47
Total tax expense (VIII)	**363.04**	**384.80**	**327.21**	**1,315.29**
IX **Profit for the period/year (VII-VIII)**	**1,258.20**	**670.92**	**984.87**	**3,406.22**
X **Other comprehensive income**				
(a) Items that will not be reclassified subsequently to profit or loss				
(i) Remeasurement gain/(loss) of net defined benefit plan	19.02	37.93	26.00	76.09
(ii) Income tax effect on above	(4.78)	(9.55)	(6.54)	(19.15)
Other comprehensive income/(losses) for the period/year, net of tax	**14.24**	**28.38**	**19.46**	**56.94**
XI **Total comprehensive income for the period/year**	**1,272.44**	**699.30**	**1,004.33**	**3,463.16**
XII **Paid-up equity share capital (face value - ₹ 2 per share)**	1,041.62	1,041.62	1,041.62	1,041.62
XIII **Other equity**				23,938.04
XIV **Earnings per equity share (Face Value of ₹ 2 each)**				
- Basic (₹) (not annualised except for year end figures)	2.42	1.29	1.89	6.54
- Diluted (₹) (not annualised except for year end figures)	2.42	1.29	1.89	6.54

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha Diagnostic Limited * Kolkata *

Notes to the unaudited standalone financial results

1. The unaudited standalone financial results for the quarter ended 30 June 2026 ("the financial results") of Suraksha Diagnostic Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").

These unaudited standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 12 August 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified conclusion.

2. The figures of the quarters ended 31 March 2026 is balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended 31 December 2025, which were subjected to limited review by the statutory auditors.

3. The Company is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –'Operating Segments'.

4. In a step-down subsidiary of the Company, a dispute with the Government of Meghalaya (the public partner) has resulted in operational losses. As a result, the recoverability of the Company's investments , loans advanced to subsidiary and trade receivables from step-down subsidiary aggregating to ₹ 393.67 lakhs as at 30 June 2026 is under assessment.

The Management has initiated arbitration proceedings through its subsidiary and the next hearing is scheduled on 21 August 2026 at the Hon'ble High Court of Meghalaya . The Company's management believes that the outcome of the arbitration will be in their favour. However, considering the dispute is subjudice, the management on prudent basis has provided ₹ 81.16 lakhs towards provisions on the said balances in the financial results.

5. These unaudited standalone financial results are also available on the Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseinda.com).

6. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha Diagnostic Limited Kolkata

For and on behalf of Board of Directors of
Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 12 August 2026

Independent Auditor's Review Report on unaudited consolidated financial results of Suraksha Diagnostic Limited for the quarter ended 30 June 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of Suraksha Diagnostic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Suraksha Diagnostic Limited (hereinafter referred to as 'the Holding Company') and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended June 30, 2026 ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the Regulations, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Suraksha Speciality LLP	Subsidiary
2	Suraksha Radiology Private Limited	Subsidiary
3	Suraksha Advanced Radiology Private Limited	Subsidiary
4	Asian Institute of Immunology and Rheumatology LLP	Subsidiary
5	Fetomat Wellness Private Limited	Subsidiary
6	Suraksha Salvia LLP	Step-down subsidiary

MSKA & ASSOCIATES LLP * Chartered Accountants *

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of six subsidiaries included in the Statement, whose interim financial results reflects total revenues of Rs. 428.70 lakhs (before consolidation adjustments), total net loss after tax of Rs. 117.84 lakhs (before consolidation adjustments) and total comprehensive income of Rs. (117.84) lakhs (before consolidation adjustments) for the quarter ended 30 June 2026, as considered in the statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of the above matter with respect to our reliance on the work done by and report of the other auditors.

For M S K A & Associates LLP (Formerly known as M S K A & Associates)
Chartered Accountants
ICAI Firm Registration No.105047W/W101187

Dipak Jaiswal
Membership No.: 063682
UDIN: 26063682BVIOSY8605

Place: Kolkata
Date: 12 August 2026

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha
Clinic & Diagnostics

Suraksha Diagnostic Limited
Registered Office : Plot no. DG-12/1, Action Area 1D, Premises no. 02-0327, New Town, Rajarhat, Kolkata 700156, West Bengal, India
(CIN : L85110WB2005PLC102265)
Website : www.surakshanet.com

Statement of unaudited consolidated financial result for the quarter ended 30 June 2026

(₹ in lakhs)

Particulars	Quarter ended			Year ended
	30 June 2026 (Unaudited)	31 March 2026 (Audited) (Refer Note 2)	30 June 2025 (Unaudited)	31 March 2026 (Audited)
Income				
I Revenue from operations	8,764.54	8,141.15	7,258.63	31,041.41
II Other income	108.77	78.54	90.57	316.41
III **Total Income**	**8,873.31**	**8,219.69**	**7,349.20**	**31,357.82**
IV **Expenses**				
Cost of materials consumed	999.50	1,015.79	875.05	3,647.54
Employee benefits expenses	1,441.18	1,367.02	1,277.47	5,325.51
Finance costs	372.21	391.57	270.49	1,255.33
Depreciation and amortisation expense	1,128.22	1,125.81	948.24	4,144.83
Impairment loss/(gain)	(5.20)	29.45	(89.04)	46.71
Other expenses	3,284.82	3,291.96	2,820.12	12,482.22
Total expenses (IV)	**7,220.73**	**7,221.60**	**6,102.33**	**26,902.14**
V **Profit before tax and exceptional items (III-IV)**	**1,652.58**	**998.09**	**1,246.87**	**4,455.68**
VI Exceptional items	-	-	-	-
VII **Profit before tax (V-VI)**	**1,652.58**	**998.09**	**1,246.87**	**4,455.68**
VIII **Income tax expense**				
(i) Current tax expense	412.92	241.36	287.82	1,077.69
(ii) Tax pertaining to earlier year	11.39	-	-	(0.05)
(iii) Deferred tax expense/(credit)	(56.27)	140.81	41.54	237.79
Total tax expense (VIII)	**368.04**	**382.17**	**329.36**	**1,315.43**
IX **Profit for the period/year (VII-VIII)**	**1,284.54**	**615.92**	**917.51**	**3,140.25**
X **Other comprehensive income**				
(a) Items that will not be reclassified subsequently to profit or loss				
(i) Remeasurement gain/(loss) of net defined benefit plan	19.02	37.93	26.00	76.09
(ii) Income tax effect on above	(4.78)	(9.55)	(6.54)	(19.15)
Other comprehensive income/(losses) for the period/year, net of tax	**14.24**	**28.38**	**19.46**	**56.94**
XI **Total comprehensive income for the period/year**	**1,298.78**	**644.30**	**936.97**	**3,197.19**
XII **Profit for the period/year attributed to**				
Owners of the parent	1,300.80	628.04	939.74	3,218.71
Non- controlling interests	(16.26)	(12.12)	(22.23)	(78.46)
	1,284.54	615.92	917.51	3,140.25
XIII **Other comprehensive income for the period/year attributable to**				
Owners of the parent	14.24	28.38	19.46	56.94
Non- controlling interests	-	-	-	-
	14.24	28.38	19.46	56.94
XIV **Total comprehensive income for the period/year attributable to**				
Owners of the parent	1,315.04	656.42	959.20	3,275.65
Non- controlling interests	(16.26)	(12.12)	(22.23)	(78.46)
	1,298.78	644.30	936.97	3,197.19
XV **Paid-up equity share capital (face value - ₹ 2 per share)**	1041.62	1,041.62	1,041.62	1,041.62
XVI **Other equity (including non-controlling interest)**				23,443.28
XVII **Earnings per equity share (Face Value of ₹ 2 each)**				
- Basic (₹) (not annualised except for year end figures)	2.50	1.21	1.80	6.18
- Diluted (₹) (not annualised except for year end figures)	2.50	1.21	1.80	6.18

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha Diagnostic Limited ★ Kolkata

Notes to the unaudited consolidated financial results

1. The unaudited consolidated financial results for the quarter ended 30 June 2026 ("the financial results") of Suraksha Diagnostic Limited ("the Holding Company") and its subsidiary (Holding company and subsidiaries together referred to as 'the group') have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and other accounting principles generally accepted in India and in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the regulations").

These unaudited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meeting held on 12 August 2026. The statutory auditor have carried out limited review on these financial results and have issued an unmodified

2. The figures of the quarters ended 31 March 2026 is balancing figures between the audited figures in respect of the full financial year and the published figures of nine months ended 31 December 2025, which were subjected to limited review by the statutory auditors.

3. The Group is primarily engaged in the business of diagnostic centres for carrying out various pathology and radiology services and as such there are no separate reportable segments as per Ind AS 108 –'Operating Segments'.

4. These unaudited consolidated financial results are also available on the Holding Company's website (www.surakshanet.com) and on the stock exchange websites (www.bseindia.com and www.nseinda.com).

5. Previous period's/year's figures have been regrouped/reclassified wherever necessary to conform to current period's/ year's classification.

MSKA & ASSOCIATES LLP * Chartered Accountants *

Suraksha Diagnostic Limited Kolkata

For and on behalf of Board of Directors of

Suraksha Diagnostic Limited

Dr. Somnath Chatterjee
Chairman & Joint Managing Director
DIN: 00137075

Place: Kolkata
Date: 12 August 2026

Annexure - B

The details as required under Schedule III - Para A (7) of Part A of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular dated 30 January, 2026 :

Sl. No.	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Mr. Dinesh Gupta as the Chief Financial Officer of the Company with effect from 24 August 2026, who will also act as a Group Chief Financial Officer of the Company.
2	Date of appointment~~/re-appointment/ cessation~~ (as applicable) & term of appointment /	The Board of Directors in their meeting held today and based on the recommendation of the Nomination and Remuneration Committee and Audit Committee had considered and approved the appointment of Mr. Dinesh Gupta as the Chief Financial Officer of the Company with effect from 24 August 2026, who will also act as a Group Chief Financial Officer of the Company.
3	Brief profile (in case of appointment)	Mr. Dinesh Gupta is a seasoned finance professional with over 14 years of experience across diverse areas of financial management. He holds a Bachelor's degree in Commerce from the University of Calcutta and has been a member of the Institute of Chartered Accountants of India since 2011. He possesses extensive expertise across a wide spectrum of finance functions, including financial planning, analysis, and strategic management. Prior to joining our Company, Mr. Dinesh Gupta served as Assistant General Manager at Saranyu Power Trading Private Limited (a group company of India Power Corporation Limited). He has also held key roles as Assistant Manager at Genpact (Kolkata), and as an Analyst in Finance & Accounts at Maersk Global Services Limited (Pune) and Gupta Deals and Merchandise Private Limited. His diverse background equips him with a robust understanding of financial management and strategic planning.
4	Disclosure of relationships between Directors (in case of appointment of a Director)	Not Applicable